AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
197.69
+0.31 (0.16%)
At close: Apr 28, 2026, 4:00 PM EDT
197.68
-0.01 (-0.01%)
After-hours: Apr 28, 2026, 5:22 PM EDT
AbbVie Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for AbbVie stock have an average target of 250.94, with a low estimate of 204 and a high estimate of 294. The average target predicts an increase of 26.94% from the current stock price of 197.69.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for AbbVie stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 4 | 4 | 5 |
| Buy | 11 | 9 | 9 | 10 | 10 | 9 |
| Hold | 6 | 5 | 7 | 6 | 6 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 19 | 21 | 20 | 20 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $299 → $294 | Buy | Maintains | $299 → $294 | +48.72% | Apr 23, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $262 | Strong Buy | Initiates | $262 | +32.53% | Apr 21, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $242 → $249 | Strong Buy | Maintains | $242 → $249 | +25.95% | Apr 10, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $250 → $240 | Buy | Maintains | $250 → $240 | +21.40% | Apr 8, 2026 |
| RBC Capital | RBC Capital | Buy Initiates $260 | Buy | Initiates | $260 | +31.52% | Feb 25, 2026 |
Financial Forecast
Revenue This Year
68.42B
from 61.16B
Increased by 11.87%
Revenue Next Year
73.98B
from 68.42B
Increased by 8.12%
EPS This Year
14.83
from 2.36
Increased by 528.36%
EPS Next Year
16.41
from 14.83
Increased by 10.66%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 70.9B | 78.0B | ||||||
| Avg | 68.4B | 74.0B | ||||||
| Low | 65.3B | 69.0B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 15.9% | 14.0% | ||||||
| Avg | 11.9% | 8.1% | ||||||
| Low | 6.7% | 0.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 16.01 | 18.30 | ||||||
| Avg | 14.83 | 16.41 | ||||||
| Low | 13.75 | 14.65 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 578.5% | 23.4% | ||||||
| Avg | 528.4% | 10.7% | ||||||
| Low | 482.6% | -1.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.